Isis discontinues development of ISIS-CRPRx for rheumatoid arthritis

08/6/2013 | Reuters

Isis Pharmaceuticals is halting development of its investigational drug ISIS-CRPRx as a treatment for rheumatoid arthritis based on the findings of a Phase II study. The drug failed to significantly outperform a placebo in the alleviation of symptoms. The firm will continue to develop the drug for other diseases, including atrial fibrillation.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Food & Drug Associate
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations